Synairgen (GB:SNG) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Synairgen plc has announced that Dr. Phillip Monk will be stepping down from the company’s Board after 18 years, effective December 31, 2024. Dr. Marcin Mankowski, who became Chief Medical Officer in 2023, will continue leading the clinical development of SNG001, Synairgen’s investigational inhaled antiviral treatment. The company also hints at upcoming Board changes as it prepares for its Annual General Meeting in early October.
For further insights into GB:SNG stock, check out TipRanks’ Stock Analysis page.
